These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 14574173)

  • 1. MRI screening for breast cancer in women with familial or genetic predisposition: design of the Dutch National Study (MRISC).
    Kriege M; Brekelmans CT; Boetes C; Rutgers EJ; Oosterwijk JC; Tollenaar RA; Manoliu RA; Holland R; de Koning HJ; Klijn JG
    Fam Cancer; 2001; 1(3-4):163-8. PubMed ID: 14574173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging.
    Saadatmand S; Tilanus-Linthorst MM; Rutgers EJ; Hoogerbrugge N; Oosterwijk JC; Tollenaar RA; Hooning M; Loo CE; Obdeijn IM; Heijnsdijk EA; de Koning HJ
    J Natl Cancer Inst; 2013 Sep; 105(17):1314-21. PubMed ID: 23940285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.
    Warner E; Plewes DB; Hill KA; Causer PA; Zubovits JT; Jong RA; Cutrara MR; DeBoer G; Yaffe MJ; Messner SJ; Meschino WS; Piron CA; Narod SA
    JAMA; 2004 Sep; 292(11):1317-25. PubMed ID: 15367553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC).
    Saadatmand S; Obdeijn IM; Rutgers EJ; Oosterwijk JC; Tollenaar RA; Woldringh GH; Bergers E; Verhoef C; Heijnsdijk EA; Hooning MJ; de Koning HJ; Tilanus-Linthorst MM
    Int J Cancer; 2015 Oct; 137(7):1729-38. PubMed ID: 25820931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study.
    Rijnsburger AJ; Obdeijn IM; Kaas R; Tilanus-Linthorst MM; Boetes C; Loo CE; Wasser MN; Bergers E; Kok T; Muller SH; Peterse H; Tollenaar RA; Hoogerbrugge N; Meijer S; Bartels CC; Seynaeve C; Hooning MJ; Kriege M; Schmitz PI; Oosterwijk JC; de Koning HJ; Rutgers EJ; Klijn JG
    J Clin Oncol; 2010 Dec; 28(36):5265-73. PubMed ID: 21079137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer.
    Warner E; Plewes DB; Shumak RS; Catzavelos GC; Di Prospero LS; Yaffe MJ; Goel V; Ramsay E; Chart PL; Cole DE; Taylor GA; Cutrara M; Samuels TH; Murphy JP; Murphy JM; Narod SA
    J Clin Oncol; 2001 Aug; 19(15):3524-31. PubMed ID: 11481359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk.
    Geuzinge HA; Obdeijn IM; Rutgers EJT; Saadatmand S; Mann RM; Oosterwijk JC; Tollenaar RAEM; de Roy van Zuidewijn DBW; Lobbes MBI; van 't Riet M; Hooning MJ; Ausems MGEM; Loo CE; Wesseling J; Luiten EJT; Zonderland HM; Verhoef C; Heijnsdijk EAM; Tilanus-Linthorst MMA; de Koning HJ;
    JAMA Oncol; 2020 Sep; 6(9):1381-1389. PubMed ID: 32729887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging.
    Plevritis SK; Kurian AW; Sigal BM; Daniel BL; Ikeda DM; Stockdale FE; Garber AM
    JAMA; 2006 May; 295(20):2374-84. PubMed ID: 16720823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial.
    Saadatmand S; Geuzinge HA; Rutgers EJT; Mann RM; de Roy van Zuidewijn DBW; Zonderland HM; Tollenaar RAEM; Lobbes MBI; Ausems MGEM; van 't Riet M; Hooning MJ; Mares-Engelberts I; Luiten EJT; Heijnsdijk EAM; Verhoef C; Karssemeijer N; Oosterwijk JC; Obdeijn IM; de Koning HJ; Tilanus-Linthorst MMA;
    Lancet Oncol; 2019 Aug; 20(8):1136-1147. PubMed ID: 31221620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer.
    Griebsch I; Brown J; Boggis C; Dixon A; Dixon M; Easton D; Eeles R; Evans DG; Gilbert FJ; Hawnaur J; Kessar P; Lakhani SR; Moss SM; Nerurkar A; Padhani AR; Pointon LJ; Potterton J; Thompson D; Turnbull LW; Walker LG; Warren R; Leach MO;
    Br J Cancer; 2006 Oct; 95(7):801-10. PubMed ID: 17016484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers.
    Cott Chubiz JE; Lee JM; Gilmore ME; Kong CY; Lowry KP; Halpern EF; McMahon PM; Ryan PD; Gazelle GS
    Cancer; 2013 Mar; 119(6):1266-76. PubMed ID: 23184400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition.
    Kriege M; Brekelmans CT; Boetes C; Besnard PE; Zonderland HM; Obdeijn IM; Manoliu RA; Kok T; Peterse H; Tilanus-Linthorst MM; Muller SH; Meijer S; Oosterwijk JC; Beex LV; Tollenaar RA; de Koning HJ; Rutgers EJ; Klijn JG;
    N Engl J Med; 2004 Jul; 351(5):427-37. PubMed ID: 15282350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of clinical breast examination in a breast cancer surveillance program for women with germline BRCA1 or BRCA2 mutations.
    Hettipathirana T; Macdonald C; Xie J; Moodie K; Michael C; Phillips KA
    Med J Aust; 2021 Nov; 215(10):460-464. PubMed ID: 34420218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should women with a BRCA1/2 mutation aged 60 and older be offered intensified breast cancer screening? - A cost-effectiveness analysis.
    Phi XA; Greuter MJW; Obdeijn IM; Oosterwijk JC; Feenstra TL; Houssami N; de Bock GH
    Breast; 2019 Jun; 45():82-88. PubMed ID: 30904701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences between first and subsequent rounds of the MRISC breast cancer screening program for women with a familial or genetic predisposition.
    Kriege M; Brekelmans CT; Boetes C; Muller SH; Zonderland HM; Obdeijn IM; Manoliu RA; Kok T; Rutgers EJ; de Koning HJ; Klijn JG;
    Cancer; 2006 Jun; 106(11):2318-26. PubMed ID: 16615112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS).
    Leach MO; Boggis CR; Dixon AK; Easton DF; Eeles RA; Evans DG; Gilbert FJ; Griebsch I; Hoff RJ; Kessar P; Lakhani SR; Moss SM; Nerurkar A; Padhani AR; Pointon LJ; Thompson D; Warren RM;
    Lancet; 2005 May 21-27; 365(9473):1769-78. PubMed ID: 15910949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density.
    Riedl CC; Luft N; Bernhart C; Weber M; Bernathova M; Tea MK; Rudas M; Singer CF; Helbich TH
    J Clin Oncol; 2015 Apr; 33(10):1128-35. PubMed ID: 25713430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer.
    Le-Petross HT; Whitman GJ; Atchley DP; Yuan Y; Gutierrez-Barrera A; Hortobagyi GN; Litton JK; Arun BK
    Cancer; 2011 Sep; 117(17):3900-7. PubMed ID: 21365619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast density as indicator for the use of mammography or MRI to screen women with familial risk for breast cancer (FaMRIsc): a multicentre randomized controlled trial.
    Saadatmand S; Rutgers EJ; Tollenaar RA; Zonderland HM; Ausems MG; Keymeulen KB; Schlooz-Vries MS; Koppert LB; Heijnsdijk EA; Seynaeve C; Verhoef C; Oosterwijk JC; Obdeijn IM; de Koning HJ; Tilanus-Linthorst MM
    BMC Cancer; 2012 Oct; 12():440. PubMed ID: 23031619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Which screening strategy should be offered to women with BRCA1 or BRCA2 mutations? A simulation of comparative cost-effectiveness.
    de Bock GH; Vermeulen KM; Jansen L; Oosterwijk JC; Siesling S; Dorrius MD; Feenstra T; Houssami N; Greuter MJ
    Br J Cancer; 2013 Apr; 108(8):1579-86. PubMed ID: 23579217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.